About this trial
Antibiotic allergy labels (AAL) are reported in 7% of inpatient's charts, especially for beta-lactams (86% of AAL, i.e., prevalence of 6%). They are associated with increased length of hospital stay, and use of second-line and broad-spectrum antibiotics. Allergy workups are able to invalidate the majority of these AAL but are time-consuming and require invasive skin and provocation testing. The investigators recently evaluated, for the first time in Europa, a strictly non-invasive delabeling protocol using a questionnaire, medical file search and contact with primary care health care workers in 200 adult internal medicine inpatients with a beta-lactam AAL. Up to half of the AAL could be removed or refined, demonstrating the potential of this strategy. In this project, they aim to assess the impact of using the non-invasive 'AAL-fact-check' tool in a multicenter study, on antibiotic selection, and clinical, antimicrobial, and economic endpoints, as compared with the standard of care (i.e., no AAL-fact-check tool).
Eligibility criteria
Qualifiers
Hospitalized patients
AAL for one or more beta-lactams
Disqualifiers
Age younger than 18
Previous enrolment in this study
Trial design
Treatments tested in this trial
- EPR search
Treatment groups
Sponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Noorderhart Pelt
Collaborator
AZ Herentals
Collaborator
Heilig Hartziekenhuis, Mol
Collaborator
AZ Turnhout
Collaborator
Sint-Jozefskliniek Izegem
Collaborator